Engflag

Coltec

Quick links to important sections

Coltec

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coltec

What is Coltec?

Coltec is a pharmaceutical formulation containing the active ingredient mesalazine, also known as 5-aminosalicylic acid (5-ASA). It belongs to a class of medications known as aminosalicylates, which are primarily used to manage inflammatory conditions of the gastrointestinal tract.

Therapeutic Purpose

The medication is designed to treat and manage chronic inflammatory bowel diseases (IBD). Its primary function is to reduce the inflammation occurring in the lining of the gut. By targeting the inflammatory process directly within the intestinal tissues, it helps to alleviate symptoms associated with active disease flares and assists in maintaining periods of remission.

Mechanisms of Action

Coltec works locally on the affected areas of the intestinal wall. While the exact biological process is complex, the medication is understood to inhibit the production of certain substances, such as prostaglandins and leukotrienes, which are known to trigger inflammation and tissue damage in the digestive system. It may also act as an antioxidant, neutralizing free radicals that contribute to the inflammatory response.

Clinical Indications

Coltec is typically utilized for the following conditions:

  • Ulcerative Colitis: It is used to treat mild to moderate episodes of inflammation in the colon and rectum, as well as to prevent the recurrence of symptoms over the long term.
  • Crohn's Disease: In certain clinical scenarios, it may be used to manage inflammation specifically affecting the colon.

Because the medication is intended to act topically within the bowel, different formulations of Coltec are designed to release the active ingredient in specific locations of the gastrointestinal tract to ensure it reaches the site of inflammation effectively.

Regulatory References

  1. U.S. National Library of Medicine (NIH)
  2. MedlinePlus Mesalamine Drug Information
  3. NIH Aminosalicylates in IBD Management

What side effects are possible with Coltec?

Possible Side Effects and Safety Information

The safety profile of Coltec, which contains Mesalamine, is defined by regulatory bodies through classifications of frequency and the body systems affected. Adverse reactions are grouped according to the official regulatory definitions, primarily based on the European frequency framework.

Officially Documented Adverse Reactions

Adverse effects are categorized based on their documented frequency in clinical use:

  • Common (affecting up to 1 in 10 people) typically include systemic reactions such as headache, abdominal pain, nausea, diarrhea, vomiting, and rash.
  • Rare (affecting up to 1 in 1,000 people) include specific hypersensitivity reactions such as pancreatitis, myocarditis (heart muscle inflammation), and pericarditis (inflammation of the sac around the heart).

Safety Constraints and Organ System Effects

The official labeling notes that adverse reactions can involve several organ systems. The most frequently documented effects relate to the Gastrointestinal Disorders and Nervous System Disorders. More serious, albeit rare, effects may involve the Renal and Urinary Disorders, including interstitial nephritis and potential renal impairment, as well as Hepato-biliary Disorders.

Regulatory documents highlight the potential for a Mesalamine-Induced Acute Intolerance Syndrome, which may appear shortly after treatment begins, characterized by fever, cramping, and bloody diarrhea. Life-threatening events, such as Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented.

Safety limitations include the official caution against use in individuals with known hypersensitivity to salicylates (like aspirin) or Mesalamine itself. Furthermore, regulatory agencies recommend particular caution in patients with pre-existing severe hepatic or renal impairment, often requiring periodic function monitoring.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation notes that data on human acute oral overdose with mesalamine (Coltec) is rare, and specific overdose symptoms are not well-established. Treatment for an overdose is mandated to be symptomatic and supportive, as no specific antidote is known.

Severe Outcomes and Emergency Action

While specific overdose symptoms are rare, official labels document the risk of life-threatening systemic reactions that require immediate medical attention. These severe outcomes include potential internal organ hypersensitivity, such as myocarditis, nephritis, and hepatitis. The risk of Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), is also documented.

The label requires patients to seek immediate medical attention for suspected severe outcomes. If signs of a systemic hypersensitivity reaction or acute intolerance syndrome are present, a prompt immediate evaluation and discontinuation of the medicine are required.

Monitoring and Risk Factors

The kidney is noted as the principal target organ for toxicity in non-clinical studies. For this reason, official guidance requires monitoring of renal function prior to and periodically during therapy. The risk of adverse reactions may be greater in individuals with impaired renal function, and discontinuation is required if renal function deteriorates.

Therapeutic Uses of Coltec

Coltec is indicated for the management of symptoms associated with chronic inflammatory conditions, helping to support comfort and maintain function across several patient populations. It may be considered by healthcare providers for individuals experiencing persistent physical discomfort and stiffness that affect daily routines. The therapeutic benefit of Coltec is primarily focused on facilitating relief from generalized unease and localized discomfort. The use of Coltec is part of a broader plan to assist in the long-term management of chronic issues, specifically addressing concerns related to joint and muscle irritation.

Quick Fact: Coltec may help with the temporary reduction of localized stiffness.

Its clinical application primarily involves the supportive care of patients with ongoing discomfort, contributing to a more comfortable experience during physical activity and rest.

Eligibility and Restrictions for Use

Who can and cannot use Coltec?

The eligibility to use Coltec (Mesalamine) is strictly defined by regulatory documents based on patient population and pre-existing conditions.

The medicine is contraindicated and must not be used by patients with a known or suspected hypersensitivity to salicylates (such as aspirin) or aminosalicylates (5-ASA). Furthermore, official labeling specifies that severe hepatic or renal impairment is an absolute contraindication for use.

Use is restricted and requires caution and monitoring in patients with pre-existing, but not severe, liver or kidney impairment. Caution is also advised when the patient is taking concomitant nephrotoxic drugs, such as certain NSAIDs, or has pre-existing skin conditions like atopic dermatitis.

Regarding age, Coltec is generally approved for adults and for certain treatments in pediatric patients 5 years of age and older who meet specific weight requirements. Use is not established in children under 5. Caution is noted for older adults due to the increased likelihood of decreased renal function.

Use during pregnancy and lactation is conditional, advised only if the benefit outweighs the potential risk, with a specific recommendation to monitor the breastfed infant for diarrhea.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for mesalamine (Coltec) is defined by officially documented risks involving metabolic pathways, organ toxicity, and pharmaceutical interference, as outlined in government regulatory information. The following interactions are noted in official labeling:

Documented Pharmacological Interactions

Interacting Substance/Class Official Interaction Outcome Type of Interaction
Azathioprine and 6-Mercaptopurine Increased risk of blood disorders (myelotoxicity) Enzyme-Mediated Exposure Modification
Nephrotoxic Agents (e.g., NSAIDs) Increased risk of renal reactions (nephrotoxicity) Pharmacodynamic (Additive Effect)

Co-administration of mesalamine with thiopurines (Azathioprine and 6-Mercaptopurine) is associated with an increased risk of severe blood dyscrasias. This effect is attributed to the documented inhibition of the enzyme thiopurine methyltransferase (TPMT), which alters the clearance of the thiopurine's active metabolites. Concurrently, the use of mesalamine with other agents known to be toxic to the kidneys, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), carries a warning due to the potential for additive adverse effects on renal function. Caution is specifically advised when administering these combinations to patients with known renal impairment.

Administration and Procedural Constraints

Certain extended-release formulations require caution with co-administration of antacids. Regulatory labeling specifies that combining these may interfere with the enteric coating, potentially altering the intended release profile of the mesalamine. Additionally, mesalamine has been officially documented to interfere with specific laboratory tests, causing spuriously elevated urinary normetanephrine test results when analyzed by liquid chromatography with electrochemical detection.

Mechanism of Action

Coltec's mechanism of action is focused on the modulation of localized inflammatory processes within the distal gastrointestinal tract through a sophisticated, multi-target strategy.

Dual Inhibition of Inflammatory Messengers

This core mechanism involves the drug acting as an inhibitor on specific enzymes, Cyclooxygenase (COX) and 5-Lipoxygenase (5-LOX). By blocking the activity of these enzymes, Mesalamine limits the synthesis of prostaglandins and leukotrienes, potent mediators of inflammation. This action modifies the acute inflammatory cascade, resulting in a decrease of mediators associated with tissue edema and irritation.

Genetic and Transcriptional Control of Inflammation

Mesalamine exerts a deeper regulatory effect by modulating the cell's genetic responses. It acts as an agonist for the nuclear receptor PPAR- gamma while simultaneously inhibiting the activation of the central inflammatory control pathway, NF- kappa B. This combined activity suppresses the transcription of pro-inflammatory genes, thereby reducing the chemotaxis and infiltration of circulating immune cells.

Local Protection and Antioxidant Scavenging

A complementary mechanism involves the drug acting as a scavenger of free radicals and Reactive Oxygen Species (ROS), which are damaging byproducts released by immune cells during inflammation. By neutralizing these unstable molecules, Mesalamine reduces the local concentration of oxidizing agents and contributes to the stability of the mucosal epithelial barrier.

Dosage and Administration Information

Instruction Map: How to use Coltec — administration guidelines

Administration Scope

Scope Component General Instruction
Route of administration Oral route via delayed/extended-release forms and Rectal route via suppository or enema suspension.
Dosing schedule (Adults) Induction: Total daily dose generally ranges from 2.4 g to 4.8 g once daily. Maintenance: Total daily dose is typically 2.4 g once daily. Rectal dose is 1000 mg once daily.
Timing in relation to meals Is formulation-dependent; oral tablets (e.g., 1.2 g) must be administered with food to ensure proper release of the active ingredient.
Preparation requirements Rectal enema suspensions require vigorous shaking immediately prior to administration.
Age-group administration rules Pediatric: Dosing for children (e.g., ge 10 years or ge 24 kg) is weight-based, with a time-limited induction phase (e.g., 8 weeks). Older Adults: Caution is advised, often recommending initiation at the lower adult dosing range.
Missed-dose rules If a dose is missed, it should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped to resume the regular schedule.
Special procedural conditions Rectal suppositories must be administered at bedtime and retained for at least one to three hours or longer, if possible.

Instruction Classifications (High-Level)

Classification Component Labeled Pattern
Administration method type Oral and Rectal.
Frequency pattern Daily (once daily or multiple times per day, depending on the specific product formulation).
Use-context constraints Use is constrained to a short-term induction course (e.g., 6 to 8 weeks) followed by long-term continuous maintenance therapy.

Resulting procedural structure

Step sequence:

  • The oral delayed-release tablets must be swallowed whole and must not be crushed, split, or chewed, ensuring the active component releases at the targeted site in the colon.
  • The oral total daily dose is administered either once daily or in divided doses, strictly following the schedule for the specific formulation prescribed.
  • For rectal administration, the dose is applied once nightly and must be retained for the duration specified in the product labeling.

Connection to the overall use protocol (2–4 sentences)

The administration instructions establish a standardized dual-route protocol, defining both oral and rectal administration patterns based on a distinction between a higher induction total daily dose and a lower maintenance total daily dose. These procedural rules ensure the active ingredient is released appropriately within the targeted section of the gastrointestinal tract and that the concentration is sustained over the long term.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Coltec

Research Evidence for Ulcerative Colitis: Addressing Periods of Heightened Symptoms

Coltec (Mesalamine) was studied for use in patients facing conditions involving periods of heightened symptoms related to mild-to-moderate active Ulcerative Colitis (UC). The scientific understanding comes primarily from short-term Randomized Controlled Trials (RCTs). These studies research examined different formulations of the medicine, comparing them to an inactive substance (placebo) to measure changes over a defined time interval, typically 6 to 8 weeks. Researchers measured key outcomes related to physical discomfort and changes in symptom scores.

Studies reported that measurements of Clinical Remission endpoints were recorded for a proportion of the patients in the Mesalamine groups by the end of the short treatment period. These findings describe patterns observed in the studies where measurements of disease activity scores documented changes in the scoring metrics used for specific symptoms. Research highlights changes measured during the study period related to the visual appearance of the colon lining (endoscopic endpoints).

However, few data are available for use in patients with more severe active UC, who generally require different types of medication. Also, short-term induction trials provide limited information for long-term outcomes beyond the initial weeks of treatment.

Research Evidence for Ulcerative Colitis: Monitoring Long-Term Symptom Patterns

Long-term clinical trials research examined Mesalamine in its role for managing UC, a condition characterized by fluctuating or episodic manifestations. These studies involved patients who had already reached a state of stability (remission) and studies monitored them over extended periods, often 6, 12, or even 24 months. The main focus was on observing the rate of cycles of stability and flare-ups, documenting how many patients experienced a relapse over the observation period.

Studies reported that the observed percentage of patients experiencing a clinical flare-up was generally lower in the Mesalamine groups compared to the placebo groups over time. This evidence was used in research exploring how symptoms change over time over extended periods. Studies report how symptoms evolved in the observed populations, measuring the sustained nature of symptom control and the ongoing appearance of the colon lining (endoscopic remission).

Research Summary for Crohn's Disease and Other Conditions

Mesalamine was studied for use in Crohn's Disease (CD), another condition involving outcomes linked to inflammatory or irritative states in the digestive tract. The evidence base here data are still emerging and is considered less definitive than the data structure for UC.

For active CD, the trials research explored short-term symptom changes. However, systematic reviews of these trials documented inconsistent findings and reported that the observed changes were often minimal. Separate trials was studied for use in patients who had undergone surgery for CD, with researchers measuring whether the medicine may impact the rate of recurrence after the operation. Consequently, there is limited information for long-term outcomes in this setting. Certainty remains low for Mesalamine's role in active CD.

Key Studies & References

  1. Mesalamine Drug Information (MedlinePlus/NIH)
  2. Aminosalicylates for maintenance of remission in ulcerative colitis (Cochrane Review)
  3. 5-Aminosalicylates for the treatment of Crohn's disease (Systematic Review)
  4. Aminosalicylates in IBD Management (NIH/PMC Review)

Frequently Asked Questions (FAQ)

Common questions about Coltec (FAQ)

Q: How quickly does Coltec start working after you take it?

Studies and official information indicate that the time it takes to see the full effect can vary. Clinical trials for treating active symptoms have typically measured effectiveness over six to eight weeks. However, rectal formulations may start to show symptom improvement sooner, sometimes within a few days to a few weeks.

Q: What is the longest time Coltec stays active in your system?

Regulatory information indicates that the drug's half-life, which is the time it takes for half of the dose to be cleared, can be highly variable. Since Coltec is designed as an extended-release medicine to act locally in the colon, its clearance time from the body depends on the specific formulation you are taking and can range from several hours to a day or more.

Q: Are there any specific vitamins or supplements that shouldn't be taken with Coltec?

Regulatory agencies advise that there is not enough clinical data on the interactions between mesalamine (the active ingredient in Coltec) and many complementary medicines, herbal remedies, or supplements. Patients may wish to consult their healthcare professional about all products they are taking.

Q: What is the difference between Coltec and similar medicines I see advertised?

Coltec contains the active ingredient mesalamine, which belongs to a class of anti-inflammatory drugs called aminosalicylates. These medicines are designed to work primarily on inflammation localized within the bowel. Other medicines used for inflammatory bowel disease (IBD) may belong to different drug classes, such as steroids or biologics, that work throughout the body or target specific parts of the immune system.

Q: Is Coltec a daily maintenance medicine or only for flare-ups?

According to the official product information, Coltec is indicated for two main uses. It is used for a short course to treat active symptoms (known as induction of remission), and it is also indicated for long-term daily use to prevent symptoms from returning (known as maintenance of remission).

Q: What are the signs that Coltec is working correctly?

The effectiveness of Coltec is clinically measured by the reduction of inflammation and symptoms. These measurements, used in studies, include achieving clinical remission and improvements in physical disease activity scores, as well as positive changes in the visual appearance of the colon lining observed through endoscopy.

Q: Can Coltec cause problems with sleeping?

Official product information for mesalamine-containing products reports that insomnia, or trouble sleeping, is a possible adverse reaction. Any sleep disturbances experienced are typically communicated to a healthcare professional.

Q: Is it okay to crush or break the Coltec tablet?

Regulatory warnings state that oral tablets and capsules must be swallowed whole and should not be cut, broken, crushed, or chewed. This approach helps maintain the integrity of the extended-release coating, which is essential for the active ingredient to be released at the targeted site in the colon.

Q: How soon after stopping Coltec will it be completely out of my system?

Official pharmacological data show that most of the absorbed active drug is rapidly changed into a different substance and excreted, primarily through urine. However, the total time required for the drug to be completely cleared from the body varies widely depending on the specific Coltec formulation.

Q: Why do doctors prescribe Coltec instead of other options?

Coltec is generally considered a first-line therapy for treating mild to moderately active ulcerative colitis and for preventing relapse. Its prescribed use is based on its established role in clinical guidelines as a locally acting anti-inflammatory agent for these specific conditions.

Q: Is Coltec ever used for conditions other than its primary indication?

The main indications for Coltec are ulcerative colitis and ulcerative proctitis. While it has been studied for use in Crohn's Disease, the evidence base is considered less definitive than for ulcerative colitis, and it may not be included in the primary indications on all product labels.

Q: Can Coltec cause changes in appetite or weight?

Regulatory documents report decreased appetite as a possible side effect of mesalamine products. Additionally, weight gain has been reported as an adverse reaction for certain formulations, though the frequency of this effect may be unknown.

Q: Is there a maximum time recommended for taking Coltec?

For treating active symptoms (induction phase), the course is typically time-limited, often six to eight weeks. However, the official product information indicates the medicine is also intended and prescribed for long-term continuous use to prevent the return of symptoms.

Q: Are there any known interactions with herbal teas?

Regulatory agencies advise that there is not enough clinical data on the interactions between mesalamine (the active ingredient in Coltec) and many herbal teas or other natural health products. Patients may wish to consult their healthcare professional about all herbal products they consume.

Q: Why does Coltec have to be stored at a specific temperature?

Coltec is required to be stored at controlled room temperature, which is a specific, narrow temperature range (typically 20 C to 25 C). This requirement helps ensure that the chemical properties of the active ingredient and the integrity of the specialized delivery system (like the tablet coating) are preserved.

Q: Why is it important to complete the full course of Coltec?

The full treatment involves two phases: a short-term period to get active symptoms under control (induction) and a long-term, continuous phase (maintenance). Following the maintenance protocol is important because it has been shown in studies to help prevent the symptoms of the condition from recurring or flaring up.

Q: Are there any known effects of Coltec on kidney function?

Official warnings state that Coltec has the potential to cause renal impairment, which includes a rare but serious condition called interstitial nephritis. Official warnings note that kidney function is typically evaluated before starting therapy and monitored periodically during treatment, in line with regulatory recommendations.

How should Coltec be stored and disposed of?

How to Store and Dispose of Mesalamine (Coltec)

The official storage requirements for this medication are defined by specific environmental and safety rules, which can vary slightly by formulation (e.g., tablet, enema).

Mandatory Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C, with brief excursions permitted up to 30 C.
Protection Keep the product protected from light and moisture.
Container The container must be kept tightly closed and use a child-resistant closure.
Handling Note The rectal suspension (enema) should not be refrigerated.

Disposal Instructions

Unused or expired mesalamine must be disposed of according to local regulations.

Regulators explicitly state that medicines must not be thrown away via household waste or wastewater; individuals should consult a pharmacist or authorized waste disposal plant for guidance on proper disposal. It is mandatory to keep this and all medication out of the reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Coltec found in:

A-Z Index: